Nanoparticle Technology To Treat Vascular Occlusions Using Much-Lower Drug Doses
This article was originally published in Start Up
New research shows that aggregates of nanoparticles will target an occluded blood vessel, responding to the higher shear force present as blood flows through the blockage. When coated with the anti-clotting drug tPA, the nanoparticles dissolve clots at one-hundredth the therapeutic dose of tPA, suggesting a much broader potential clinical use for that drug. This proof of concept also suggests that the nanoparticle technology may be applied to target any disease characterized by vessel constriction, including stroke and heart attack.
You may also be interested in...
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.
Recent clinical data using antisense drugs in neurological diseases are encouraging signs that targeting genetic drivers of ALS with antisense oligonucleotides or other gene-altering drugs could halt progression of several forms of the disease.